|
1 Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin Oncol, 2007, 34(suppl 2)：s1–15.
|
|
2 Belpomme D, Krakowski I, Beauduin M, et al. Gemcitabine combined with cisplatin as first–line treatment in patients with epithelial ovarian cancer: A phase Ⅱ study. Gynecol Oncol, 2003, 91(1): 32–38.
|
|
3 Gallardo D, Calderillo G, Serrano A, et al. A phase Ⅱ study of gemcitabine plus cisplatin in previously untreated advanced ovarian cancer. Anticancer Res, 2006, 26(4B): 3137–3141.
|
|
4 Nogué M, Cirera L, Arcusa A, et al. Phase Ⅱ study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anticancer Drugs, 2002, 13(8): 839–845.
|
|
5 Bauknecht T, Hefti A, Morack G, et al. Gemcitabine combined with cisplatin as first–line treatment in patients 60 years or older with epithelial ovarian cancer: A phase Ⅱ study. Int J Gynecol Cancer, 2003, 13(2): 130–137.
|
|
6 Shaharyar, Shami N, Mahmood I, et al. A phase Ⅱ trial of gemcitabine and cisplatin combination chemotherapy in advanced epithelial ovarian cancer with bulky residual disease. Proc Am Soc Clin Oncol, 2002, 21: A2518.
|
|
7 Ruiz G, Alexander F, Rodriguez G, et al. Gemcitabine plus ciplatin as first line therapy for advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol, 2002, 21: A852.
|
|
8 Tay SK, Ilanchadran A, Tan TY. First–line gemcitabine and carboplatin in advanced ovarian carcinoma: A phase Ⅱ study. BJOG, 2006, 113(12): 1388–1392.
|
|
9 Gupta SK, John S, Naik R, et al. A multicenter phase Ⅱ study of gemcitabine, paclitaxel, and cisplatin in chemonaive advanced ovarian cancer. Gynecol Oncol, 2005, 98(1): 134–140.
|
|
10 Hansen SW. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol, 2002, 29(1): 17–19.
|
|
11 Hensley ML, Correa DD, Thaler H, et al. Phase Ⅰ/Ⅱ study of weekly paclitaxel plus carboplatin and gemcitabine as first–line treatment of advanced–stage ovarian cancer: Pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol, 2006, 102(2): 270–277.
|
|
12 Friedlander M, Buck M, Wyld D, et al. Phase Ⅱ study of carboplatin followed by sequential gemcitabine and paclitaxel as first–line treatment for advanced ovarian cancer. Int J Gynecol Cancer, 2007, 17(2): 350–358.
|
|
13 Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum–sensitive recurrent ovarian cancer: An intergroup trial of the AGO–OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol, 2006, 24(29): 4699–4707.
|
|
14 Pectasides D, Xiros N, Papaxoinis G, et al. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel–pretreated, ovarian carcinoma. Gynecol Oncol, 2008, 108(1): 47–52.
|
|
15 Lorusso D, Stefano AD, Fanfani F, et al. Role of gemcitabine in ovarian cancer treatment. Ann Oncol, 2006, 17(suppl 15): v188–v194.
|
|
16 Mutch DG, Orlando M, Goss T, et al. Randomized phase Ⅲ trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum–resistant ovarian cancer. J Clin Oncol, 2007, 25(9): 2811–2818.
|
|
17 Ferrandina G, Ludovisi M, Lorusso D, et al. Phase Ⅲ trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol, 2008, 6(26): 890–896.
|
|
18 Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in platinum–refractory ovarian or primary peritoneal cancer: A phase Ⅱ study of the Gynecologic Oncology Group. Gynecol Oncol, 2006, 103(2): 446–450.
|
|
19 Bozas G, Bamias A, Koutsoukou V, et al. Biweekly gemcitabine and cisplatin in platinum–resistant/refractory, paclitaxel–pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol, 2007, 104(3): 580–585.
|
|
20 Tewari D, Monk BJ, Hunter M, et al. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum–resistant ovarian and peritoneal carcinoma. Invest New Drugs, 2004, 22(4): 475–480.
|
|
21 Lehoczky O, Pulay T. Experience with gemcitabine–carboplatin chemotherapy in relapsed ovarian cancer. Orv Hetil, 2006, 147(30): 1405–1408.
|
|
22 Germano D, Rosati G, Manzione L．Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: A single institution experience. J Chemother, 2007, 19(5): 577–581.
|
|
23 Kalykaki A, Papakotoulas P, Tsousis S, et al. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: A multicenter phase Ⅱ study of the Hellenic Oncology Research Group (HORG). Anticancer Res, 2008, 28(1B): 495–500.
|
|
24 Harnett P, Buck M, Beale P, et al. Phase Ⅱ study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: An Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer, 2007, 17(2): 359–366.
|
|
25 Skarlos DV, Kalofonos HP, Fountzilas G, et al. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase Ⅱ study. Anticancer Res, 2005, 25(4): 3103–3108.
|
|
26 Petru E, Angleitner–Boubenizek L, Reinthaller A, et al. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum–refractory and –resistant ovarian cancer after previous platinum–taxane therapy: A phase Ⅱ Austrian AGO study. Gynecol Oncol, 2006, 102(2): 226–229.
|
|
27 Tas F, Guney N, Derin D, et al. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum–resistant epithelial ovarian cancer. Int J Clin Oncol, 2008, 13(2): 156–160.
|
|
28 Galligioni E, Arcuri C, Sorio R, et al. Gemcitabine and anthracyclines in platinum–resistant ovarian cancer. Ann Oncol, 2006, 17(Suppl 5): v195–198.
|
|
29 Garcia AA, O'Meara A, Bahador A, et al. Phase Ⅱ study of gemcitabine and weekly paclitaxel in recurrent platinum resistant ovarian cancer. Gynecol Oncol, 2004, 93(2): 493–498.
|
|
30 Poole CJ, Perren T, Gawande S, et al. Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: A phase Ⅰ trial in patients with recurrent ovarian cancer. Int J Gynecol Cancer, 2006, 16(2): 507–514.
|
|
31 Goff BA, Holmberg LA, Veljovich D，et al. Treatment of recurrent or persistent platinum–refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: A phase Ⅱ trial of the Puget Sound Oncology Consortium. Gynecol Oncol, 2008, 110(2): 146–151.
|
|
32 Sehouli J, Stengel D, Oskay–Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: Results of a phase Ⅲ study of the North–Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol, 2008, 26(19): 3176–3182.
|
|
33 Makhija S, Glenn D, Ueland F, et al. 5002 ORAL Results from a phase Ⅱ randomized, placebo–controlled, double–blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum–resistant ovarian, fallopian tube, or primary peritoneal cancer. Eur J Cancer, 2007, 4(Suppl 5): 311–312.
|